^
    Back
    Association details:
    Biomarker:Chr del(5q)
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

    Published date:
    11/06/2019
    Excerpt:
    Certain cytogenetic features correlated with greater sensitivity to Rux+Ven (e.g. t(9;11) - MLL-rearrangement) or decreased sensitivity (e.g. t(15;17) - PML-RARA or monosomy 5/del 5q).
    DOI:
    https://doi.org/10.1182/blood-2019-126020